Skip to search formSkip to main contentSkip to account menu

LBH589

Known as: (2E)-N-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)prop-2-enamide, LBH 589, NVP-LBH589 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

panobinostat

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
Review
2011
Review
2011
Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells
Genomic instability is a common feature of cancer etiology. This provides an avenue for therapeutic intervention, since cancer… 
Highly Cited
2009
Highly Cited
2009
LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate.
Histone deacetylase inhibitors (HDACi) are potential candidates for therapeutic approaches in cancer and neurodegenerative… 
Highly Cited
2009
Highly Cited
2009
The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer
Lung cancer is the leading cause of cancer deaths in the United States. Current therapies are inadequate. Histone deacetylase… 
Review
2009
Review
2009
Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors.
The deacetylase inhibitors are a structurally diverse class of targeted antineoplastic agents that have demonstrated in vitro and… 
Highly Cited
2007
Highly Cited
2007
Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor–dependent human lung cancer cells
Activating mutations in the epidermal growth factor receptor (EGFR) selectively activate signal transducers and activators of… 
Highly Cited
2006
Highly Cited
2006
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
Multiple myeloma represents an incurable disease, for which development of new therapies is required. Here, we report the effect… 
Highly Cited
2006
Highly Cited
2006
Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer.
Histone deacetylases (HDAC) have been identified as therapeutic targets due to their regulatory function in DNA structure and… 
Highly Cited
2006
Highly Cited
2006
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells.
AMN107 (Novartis Pharmaceuticals, Basel, Switzerland) has potent in vitro and in vivo activity against the unmutated and most… 
Highly Cited
2005
Highly Cited
2005
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
Present studies show that LBH589, a novel cinnamic hydroxamic acid analog histone deacetylase inhibitor, induces acetylation of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)